Pharmaceuticals, Biotechnology and Life Sciences
The data showed that tiragolumab plus Tecentriq was well-tolerated and no new safety signals were identified when adding tiragolumab to Tecentriq.
Redx has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) for Zelasudil, which is currently in a Phase 2a clinical study for IPF, with topline data expected in Q1 2024.
The Company to host an earnings conference call via webcast VICTORIA, British Columbia–(BUSINESS WIRE)–$IPA #AI–IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”…
Launching in the fourth largest aesthetic toxin injectables market in Europe1 is part of the company’s geographic expansion strategy GP…
Moderna said Monday that both of its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared…
In recent years, there has been an industry-wide recognition of the need for speed and agility. Accelerating the trial processes for COVID-19 vaccine candidates required proactive and cooperative efforts from participants at all points in the supply chain. A sense of urgency and an expectation that trials should be completed more quickly and effectively emerged as a result of the realization that a drug can be approved and released to the market in a relatively short period of time. In light of this, improving the speed, accuracy, and agility of clinical trials labeling — and more specifically, the translation of label content — is one of the crucial areas that would help organizations to achieve this.
The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of Pfizer BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age.
Tevogen Bio® and Founding CEO are nominated for the 2023 Nobel Peace Prize by Curtis Patton, PhD, Professor Emeritus, Yale…
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech…
Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.